Healtcare Measles, Mumps and Rubella (MMR) Vaccines Market

Measles, Mumps and Rubella (MMR) Vaccines
Market, by Product Type, End Users and
Region - Global Industry Insights, Trends,
Outlook, and Opportunity Analysis, 2018 –
2026
Measles, mumps, and rubella are the three common contagious airborne diseases that are highly
caused by virus transmitted by sneezing and coughing of the infected person, which could lead to
serious complications or death among children. Vaccines of these diseases are sold as attenuated
viral vaccines, manufactured in a lyophilised formulation, which requires reconstitution with water
for injection diluent and are available in two forms i.e. monovalent as well as combinational
vaccines. Combinational MMR vaccines comprises mixture of two or more viral strains. These
measles, mumps, and rubella vaccines are administered by subcutaneous injection to children as
well as adults. It is generally administered to children aged 1 year and second dosage can be
administered as early as one month after the first dose. According to CDC, two doses of measles,
mumps and rubella vaccine are 97% effective against measles and 88% effective against mumps.
One dose of measles, mumps, and rubella vaccine is 93% effective against measles, 78% effective
against mumps, and 97% effective against rubella.
Currently, few vaccines available in the measles, mumps, and rubella vaccine market are sold under
the trade name of M-M-R II, ProQuad, and Attenuvax by Merck Co. Inc.; Varilrix, Priorixtetra and
MMR by GSK; Trimovax by Sanofi Pasteur and Tresivac by Serum Institute of India.
Measles, Mumps, and Rubella Vaccine Market Drivers
Vaccine manufacturers are focusing on partnering with organizations such WHO, UNICEF, and
GAVI Alliance to improve their vaccination programs, in order to reach the maximum population to
offer vaccines. In spite of several governmental initiatives, measles is a leading cause of death
among young children. Therefore, increasing success rate of vaccination programmes depends on
government initiatives of each country. Some organizations are focusing on initiative, in order to
reduce the prevalence of these diseases. For instance, GAVI Alliances has undertaken an initiative